Unphosphorylated STAT3 modulates alpha7 nicotinic receptor signaling and cytokine production in sepsis
暂无分享,去创建一个
E. P. van der Zanden | W. D. de Jonge | E. Deitch | L. Ulloa | B. Cai | Geber Peña | Jun Liu | Esmerij P. van der Zanden | Wouter J de Jonge
[1] E. Deitch,et al. JAK2 inhibition prevents innate immune responses and rescues animals from sepsis , 2010, Journal of Molecular Medicine.
[2] E. Deitch,et al. Scientific and clinical challenges in sepsis. , 2009, Current pharmaceutical design.
[3] Hua Yu,et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.
[4] M. West,et al. Does Splenectomy Protect Against Immune-Mediated Complications in Blunt Trauma Patients? , 2009, Molecular medicine.
[5] S. Akira,et al. Bacterial Endotoxin Induces the Release of High Mobility Group Box 1 via the IFN-β Signaling Pathway1 , 2009, The Journal of Immunology.
[6] G. Stark,et al. Roles of unphosphorylated STATs in signaling , 2008, Cell Research.
[7] D. Angus. Caring for the Critically Ill PatientChallenges and Opportunities , 2007 .
[8] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[9] H. Yin,et al. ROLE OF JANUS KINASE/SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION PATHWAY IN REGULATION OF EXPRESSION AND INFLAMMATION-PROMOTING ACTIVITY OF HIGH MOBILITY GROUP BOX PROTEIN 1 IN RAT PERITONEAL MACROPHAGES , 2007, Shock.
[10] J. McMurray. A new small-molecule Stat3 inhibitor. , 2006, Chemistry & biology.
[11] Bianca Sperl,et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.
[12] L. Ulloa,et al. High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.
[13] V. Pavlov,et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis , 2006, The Journal of experimental medicine.
[14] Haichao Wang,et al. Role of HMGB1 in cardiovascular diseases. , 2006, Current opinion in pharmacology.
[15] W. Parrish,et al. HMGB-1 AS A THERAPEUTIC TARGET FOR INFECTIOUS AND INFLAMMATORY DISORDERS , 2006, Shock.
[16] H. Berthoud,et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway , 2005, Nature Immunology.
[17] L. Ulloa. The vagus nerve and the nicotinic anti-inflammatory pathway , 2005, Nature Reviews Drug Discovery.
[18] Kevin J. Tracey,et al. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.
[19] K. Tracey,et al. The "cytokine profile": a code for sepsis. , 2005, Trends in molecular medicine.
[20] K. Tracey,et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.
[21] C. Dinarello. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. , 2004, Current opinion in pharmacology.
[22] H. Suh,et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis , 2004, Nature Medicine.
[23] S. Akira,et al. Aberrant Inflammation and Lethality to Septic Peritonitis in Mice Lacking STAT3 in Macrophages and Neutrophils 1 , 2003, The Journal of Immunology.
[24] Peter A. Ward,et al. Novel strategies for the treatment of sepsis , 2003, Nature Medicine.
[25] E. Fikrig,et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[26] Kevin J. Tracey,et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation , 2002, Nature.
[27] M. Feldmann,et al. Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.
[28] G. Clermont,et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.
[29] R. Bucala,et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.
[30] K. Tracey,et al. HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.
[31] S. Akira,et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.
[32] Georges E. Grau,et al. TNF inhibition and sepsis — sounding a cautionary note , 1997, Nature Medicine.
[33] S. Akira,et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] T. Hirano,et al. A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.
[35] A. Levitzki,et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.
[36] L. Moldawer,et al. BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.
[37] R. Newcombe,et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. , 1995, The New England journal of medicine.
[38] D. Remick,et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.
[39] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.